Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.
Michael Gnant
Consultant or Advisory Role - Novartis
Honoraria - AstraZeneca; Novartis
Research Funding - AstraZeneca; NanoString Technologies; Novartis
Mitchell Dowsett
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Martin Filipits
Research Funding - Sividon Diagnostics
Elena Lopez-Knowles
No relevant relationships to disclose
Richard Greil
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Marija Balic
No relevant relationships to disclose
John W Cowens
Employment or Leadership Position - NanoString Technologies
Stock Ownership - NanoString Technologies
Torsten O. Nielsen
Consultant or Advisory Role - Bioclassifier
Research Funding - NanoString Technologies
Carl Shaper
No relevant relationships to disclose
Ivana Sestak
No relevant relationships to disclose
Christian Fesl
No relevant relationships to disclose
Jack M. Cuzick
Honoraria - AstraZeneca
Research Funding - AstraZeneca